• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Effects of baloxavir and oseltamivir antiviral therapy on the transmission of seasonal influenza in China: a mathematical modeling ana

tetano

Editor, Senior Moderator
J Med Virol


. 2022 Jun 30.
doi: 10.1002/jmv.27969. Online ahead of print.
Effects of baloxavir and oseltamivir antiviral therapy on the transmission of seasonal influenza in China: a mathematical modeling analysis


Yawen Jiang[SUP] 1 [/SUP], Yi-Fan Lin[SUP] 1 [/SUP], Si Shi[SUP] 1 [/SUP], Daqin Chen[SUP] 1 [/SUP], Yuelong Shu[SUP] 1 [/SUP]



Affiliations

Abstract

New antiviral influenza treatments can effectively alleviate illness while reducing viral shedding. However, how such effects can translate into lower population infections of seasonal influenza in China remains unknown. To shed light on the public health impacts of novel antiviral agents for influenza, we constructed a dynamic transmission model to simulate the seasonal influenza epidemics in China. Two antivirus treatments, baloxavir and oseltamivir, were evaluated by estimating their impacts on the incidences of influenza infection in a single flu season. In the base-case analysis of 10% antiviral treatment uptake rate, 2,760 and 3,420 per 10,000 persons contracted influenza under the treatment of baloxavir and oseltamivir, respectively. These incidence rates amounted to a 18.90% relative risk reduction (RRR) of infection associated with baloxavir in relation to oseltamivir. The corresponding RRR was 82.16% when the antiviral treatment uptake rate was increased to 35%. In addition, the peak of the prevlance of infected individuals (per 10,000 persons) under the baloxavir treatment was 177 (Range: 93 to 274) fewer than that of oseltamivir. Our analyses suggest that the baloxavir treatment strategy reduces the incidence of influenza in China compared with oseltamivir in the setting of a seasonal flu epidemic. Also, increasing the uptake rate of antiviral treatment can potentially prevent millions of infections during a single flu season. This article is protected by copyright. All rights reserved.

Keywords: Baloxavir marboxil.; Seasonal influenza; Stochastic dynamic model.
 
Back
Top Bottom